IQ-AI Limited

Headquartered in Saint Helier, Jersey, IQ-AI Limited is a technology firm that develops sophisticated software solutions for the healthcare sector, with operations extending to the United States. Its diverse product suite supports medical imaging and diagnostics. Key offerings include IB Clinic, a set of post-processing plug-ins designed to enhance existing image visualization platforms; IB Rad Tech, an engine for streamlining custom clinical workflows; and IB Neuro, which processes MR data to create detailed parametric perfusion maps. The company also provides IB Delta Suite for essential radiology functions such as image co-registration and subtraction. Specialized tools further include IB DCE for analyzing T1-weighted images to derive perfusion and permeability parameters, and IB Diffusion for generating various parameter maps from MR diffusion-weighted data, such as apparent diffusion coefficients and IVIM. Additionally, IB StoneChecker assists clinical decision-making related to kidney stones. Beyond these software innovations, IQ-AI Limited offers valuable consulting services. The company adopted its current name in October 2018, having previously operated as Flying Brands Limited.

IQ-AI Limited trades as IQAI.L on LSE. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in GBP.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £750,105 of revenue and -£327,103 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

IQ-AI Limited can be compared against peers such as Cel AI PLC, Destiny Pharma plc, DeepVerge plc, Hellenic Dynamics Plc, Kanabo Group Plc, LungLife AI, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £2.04M, beta of 2.60, and return on equity of -108.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IQAI.L currently shows total debt of £0 and beta of 2.60. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.imagingbiometrics.com/iq-ai-ltd

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.